Successful treatment of resistant hypertension with renal denervation treatment in a patient with multiple morbidities including multivessel atherosclerotic disease, chronic kidney disease, and glucose intolerance

Neurologia Croatica

Volumn 62, Issue 2 SUPPL., 2013, Pages 11-14

  Prkačin, Ingrid ^a   Marković, Matija ^a   Cavrić, Gordana ^a   Vidjak, Vinko ^a  

^a University of Zagreb   (Croatia)

Author keywords

Chronic TH; Cost benefi t analysis; Hypertension EC; Renal insuffi ciency; Sympathetic denervation TH; TH

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALLOPURINOL; AMIODARONE; ANTIHYPERTENSIVE AGENT; CARVEDILOL; CLOPIDOGREL; FUROSEMIDE; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOSORBIDE MONONITRATE; LERCANIDIPINE; MOXONIDINE; POTASSIUM; TRIMETAZIDINE; URAPIDIL; CHOLESTEROL; CREATININE; GLUCOSE; TRIACYLGLYCEROL;

AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CAROTID ARTERY DISEASE; CASE REPORT; CHRONIC KIDNEY DISEASE; COMORBIDITY; CORONARY ARTERY DISEASE; CORONARY STENT; DIASTOLIC BLOOD PRESSURE; GLUCOSE INTOLERANCE; HEART ATRIUM FIBRILLATION; HUMAN; KIDNEY DENERVATION; MALE; MEDICATION COMPLIANCE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POTASSIUM BLOOD LEVEL; REFERENCE VALUE; RESISTANT HYPERTENSION; SYSTOLIC BLOOD PRESSURE; ALBUMINURIA; ARTIFICIAL HEART PACEMAKER; CARDIOVASCULAR STENT; CHOLESTEROL BLOOD LEVEL; CREATININE BLOOD LEVEL; HOSPITAL ADMISSION; KIDNEY FAILURE; MORBIDITY; OBESITY; PATIENT COMPLIANCE; PATIENT HISTORY OF THERAPY; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84897423168     PISSN: 03538842     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Mansia G, De Backer G, Dominiczak A et al. 2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press 2007; 16: 135-232.
2. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011; 57: 1076-80.
3. de la Sierra A, Segura J, Banegas JR et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011; 57: 898-902.
4. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2): a randomised controlled trial. Lancet 2010; 376: 1903-9.
5. Witkowski A, Prejbisz A, Florczak E et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 2011; 58: 559-65.
6. Brandt MC, Mahfoud F, Reda S et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol 2012; 59: 901-9.
7. Alvarez-Alvarez B, Abad-Cardiel M, Fernandez-Cruz A, Martell-Claros N. Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin-Angiotensin-Aldosterone system. J Hypertens 2010; 28: 2329-35.
8. Prkacin I, Balenovic D, Jurina A et al. Underestimated frequency of resistant hypertension in predialysis non diabetes patients. Acta Med Croatica 2012; 66: 229-33.